(Q40490161)

21 September 2017

title

Phase I clinical trial of topotecan and pegylated liposomal doxorubicin (English)

1 reference

21 September 2017

main subject

phase I clinical trial

0 references

2

Lynda Roman

1 reference

21 September 2017

Agustin A Garcia

1

1 reference

21 September 2017

Laila Muderspach

3

1 reference

21 September 2017

Anne O'meara

4

1 reference

21 September 2017

Grace Facio

5

1 reference

21 September 2017

Susan Edwards

6

1 reference

21 September 2017

Alexander Burnett

7

1 reference

21 September 2017

publication date

1 January 2005

1 reference

21 September 2017

1 reference

21 September 2017

volume

23

1 reference

21 September 2017

issue

8

1 reference

21 September 2017

page(s)

665-670

1 reference

Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

A phase I study of liposomal doxorubicin (Doxil) with topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

Update on the role of topotecan in the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500359877

10.1080/07357900500359877

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference